- Global Pharma News & Resources

Nexstim Plc to host a Conference Call / Webcast to Present New Depression Led Corporate Strategy

Press release, Helsinki, 25 th September 2018 at 9:00 AM EEST

Nexstim Plc to host a Conference Call / Webcast
to Present New Depression Led Corporate Strategy

Nexstim Plc (NXTMH:HEX, NXTMS:STO) (" Nexstim " or the " Company "), the targeted neuromodulation company developing and marketing navigated personalised, non-invasive brain stimulation systems for the treatment of Major Depressive Disorder (MDD), announces that the Company will hold a conference call today, Tuesday 25 th September 2018 to present its new corporate strategy.

The conference call will be hosted by Chief Executive Officer, Martin Jamieson,  Chief Financial Officer,  Mikko Karvinen and Vice President and General Manager, North America, Steve Beller.


Conference Call/ Webcast Details

Tuesday 25 th September 2018 at 4:00 p.m. EEST  (3:00 p.m. CEST / 9:00 a.m. EDT).

The dial-in numbers for the conference call are:

FI: +358 (0)9 7479 0361
SE: +46 (0)8 5664 2753
UK: +44 (0)330 336 9128
US: +1 929-477-0402

Confirmation Code:  8851156

The presentation will also be webcast and can be accessed from the following web address:


Further information is available on the website or by contacting:

Nexstim                                           +44 771 516 3942
Martin Jamieson, Chairman and CEO

Citigate Dewe Rogerson         +44 (0)207 2822949
David Dible/ Shabnam Bashir/ Sylvie Berrebi

About Nexstim Plc

Nexstim is a medical technology company focused on the development  and commercialization of its world-leading SmartFocus TM  TMS technology, a non-invasive brain stimulation system for the treatment of Major Depressive Disorder (MDD). The Company's proprietary Navigated Brain Therapy (NBT®) system, a highly sophisticated 3D navigation, is the only personalised, navigated transcranial magnetic stimulation (TMS) approach providing accurate targeting of the TMS to the specific area of the brain associated with MDD.

Nexstim's NBT® system has been launched in the US for the treatment of MDD following clearance from the FDA for marketing and commercial distribution for this indication. The NBT® system is CE marked in Europe for the treatment of major depression and chronic neuropathic pain.

In addition, Nexstim is commercialising its Navigated Brain Stimulation (NBS) system for diagnostic applications, based on the same technology. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit .

Nexstim Plc to host a Conference Call

This announcement is distributed by West Corporation on behalf of West Corporation clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Nexstim Oyj via GlobeNewswire

Editor Details

Last Updated: 26-Sep-2018